BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
See the metal guts of a satellite in this wild X-ray view | Space photo of the day for Dec. 4, 2025 - 2Step into Nature: A Survey of \Handling Trails with Solace\ Climbing Shoes
- 3Figurine of a woman and a goose offers peek at prehistoric beliefs
- 4Party Urban areas of the World
- 5Vote in favor of your Favored Travel Movement
- We tasted one of the 10,000 Hershey's Dubai chocolate bars being resold on eBay. Is it worth the hype?
- Charli xcx recorded original songs for 'Wuthering Heights' — what to know about the new album for Margot Robbie's film
- Merz: 80% of Syrians in Germany expected to return within three years
- Find Serenity: 10 Stunning Setting up camp Areas
- Top Pastry: What's Your Sweet Treat of Decision?
- FDA approves Wegovy pill for weight loss: What to know
- Find Exemplary Scents: An Extensive Aide
- Partner of crime boss Steven Lyons arrested in Dubai
- Most loved Seared Chicken: Which Chain Rules?
